# Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy

Study · id `cardio:ct-nct02517320` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02517320](<https://clinicaltrials.gov/study/NCT02517320>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02517320

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 293 participants.

## Technical summary

Registry record NCT02517320. Randomized; quadruple masking; primary purpose treatment. Start 2015-07 (registry gives no type); primary completion 2016-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 293 participants (enrolled count; ClinicalTrials.gov record NCT02517320, source copy `cardio:ctgov-nct02517320-2017-03-03`, retrieved 2026-10-26)
- Start date: 2015-07 (registry gives no type) (ClinicalTrials.gov record NCT02517320, source copy `cardio:ctgov-nct02517320-2017-03-03`, retrieved 2026-10-26)
- Primary completion: 2016-11 (actual) (ClinicalTrials.gov record NCT02517320, source copy `cardio:ctgov-nct02517320-2017-03-03`, retrieved 2026-10-26)
- Completion: 2017-01 (actual) (ClinicalTrials.gov record NCT02517320, source copy `cardio:ctgov-nct02517320-2017-03-03`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02517320, source copy `cardio:ctgov-nct02517320-2017-03-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02517320-2017-03-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy
- Condition: Diabetic Nephropathy
- Intervention (Drug): MT-3995 Low
- Intervention (Drug): MT-3995 Middle
- Intervention (Drug): MT-3995 High
- Intervention (Drug): Placebo
- Lead sponsor: Tanabe Pharma Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Tanabe Pharma Corporation (`cardio:org-tanabe-pharma-corporation`)

## Provenance

Content hash: a5908f638195c6d2eb2b094c596532f23ee8fbc50620f93766630d585f7407a3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
